BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36189508)

  • 21. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer.
    Chen WT; Gao X; Han XD; Zheng H; Guo L; Lu RQ
    Asian Pac J Cancer Prev; 2014; 15(1):101-5. PubMed ID: 24528007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.
    Granato T; Midulla C; Longo F; Colaprisca B; Frati L; Anastasi E
    Tumour Biol; 2012 Oct; 33(5):1335-9. PubMed ID: 22528938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
    Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
    Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
    Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
    Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.
    Ruggeri G; Bandiera E; Zanotti L; Belloli S; Ravaggi A; Romani C; Bignotti E; Tassi RA; Tognon G; Galli C; Caimi L; Pecorelli S
    Clin Chim Acta; 2011 Jul; 412(15-16):1447-53. PubMed ID: 21557935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
    Innao P; Pothisuwan M; Pengsa P
    Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
    Moore RG; Blackman A; Miller MC; Robison K; DiSilvestro PA; Eklund EE; Strongin R; Messerlian G
    Gynecol Oncol; 2019 Jul; 154(1):150-155. PubMed ID: 30992143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK; Chen CA; Nam JH; Ochiai K; Wilailak S; Choon AT; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Sumpaico WW
    Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
    PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. circDENND4C, a novel serum marker for epithelial ovarian cancer, acts as a tumor suppressor by downregulating miR-200b/c.
    Liu S; Yuan L; Li J; Liu Y; Wang H; Ren X
    Ann Med; 2023 Dec; 55(1):908-919. PubMed ID: 36896567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.